Published in J Cereb Blood Flow Metab on August 01, 1997
Insulin, Central Dopamine D2 Receptors, and Monetary Reward Discounting in Obesity. PLoS One (2015) 1.44
A comparison of D2 receptor specific binding in obese and normal-weight individuals using PET with (N-[(11)C]methyl)benperidol. Synapse (2013) 1.07
Characterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET. Synapse (2012) 1.01
Decreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect? Mov Disord (2010) 0.96
Neuroimaging in Parkinson's disease. Neurotherapeutics (2011) 0.95
Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates. Eur J Nucl Med Mol Imaging (2007) 0.84
Emotional Eating Phenotype is Associated with Central Dopamine D2 Receptor Binding Independent of Body Mass Index. Sci Rep (2015) 0.82
Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans. Nucl Med Biol (2008) 0.81
Spatial reorganization of putaminal dopamine D2-like receptors in cranial and hand dystonia. PLoS One (2014) 0.80
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [(11)C](+)PHNO. Neuropsychopharmacology (2016) 0.78
Prediction of striatal D2 receptor binding by DRD2/ANKK1 TaqIA allele status. Synapse (2016) 0.77
Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation. J Nucl Med (1983) 5.39
Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology (2001) 4.74
Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med (1983) 4.72
Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol (1997) 3.25
A stereotactic method of anatomical localization for positron emission tomography. J Comput Assist Tomogr (1985) 3.13
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
Neurologist care in Parkinson disease: a utilization, outcomes, and survival study. Neurology (2011) 2.61
Reduced uptake of [¹⁸F]FDOPA PET in asymptomatic welders with occupational manganese exposure. Neurology (2011) 2.53
Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology (2005) 2.41
Brain blood volume, flow, and oxygen utilization measured with 15O radiotracers and positron emission tomography: revised metabolic computations. J Cereb Blood Flow Metab (1987) 2.33
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
Standardized mean regional method for calculating global positron emission tomographic measurements. J Cereb Blood Flow Metab (1985) 2.21
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol (2001) 2.20
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2001) 2.15
Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev (1999) 1.93
Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol (1983) 1.88
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Evaluation of a screening questionnaire for genetic studies of Parkinson's disease. Am J Med Genet (1999) 1.86
Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med (1982) 1.85
Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science (1994) 1.73
Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease. J Clin Invest (1975) 1.70
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Cortical and subcortical blood flow effects of subthalamic nucleus stimulation in PD. Neurology (2003) 1.66
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med (1999) 1.62
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology (2010) 1.58
Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med (1993) 1.56
Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol (1989) 1.56
Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med (1983) 1.55
Breast cancer: PET imaging of estrogen receptors. Radiology (1988) 1.53
Unilateral vs. bilateral STN DBS effects on working memory and motor function in Parkinson disease. Exp Neurol (2007) 1.53
The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol (1998) 1.52
Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology (1989) 1.51
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med (2001) 1.51
Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med (1999) 1.49
Template images for nonhuman primate neuroimaging: 1. Baboon. Neuroimage (2001) 1.49
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology (1987) 1.49
Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. Am J Physiol (1976) 1.48
Feasibility of time-of-flight reconstruction in positron emission tomography. J Nucl Med (1980) 1.48
Regional asymmetries of cerebral blood flow, blood volume, and oxygen utilization and extraction in normal subjects. J Cereb Blood Flow Metab (1987) 1.48
In vivo comparison of copper blood-pool agents: potential radiopharmaceuticals for use with copper-62. J Nucl Med (1991) 1.46
Stimulation of STN impairs aspects of cognitive control in PD. Neurology (2004) 1.44
Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci (1997) 1.43
In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol (1990) 1.42
Novel THAP1 sequence variants in primary dystonia. Neurology (2010) 1.42
Diagnostic implications of spectral and temporal analysis of the entire cardiac cycle in patients with ventricular tachycardia. Circulation (1991) 1.41
Technology assessment revisited: does positron emission tomography have proven clinical efficacy? Neurology (1991) 1.39
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol (2001) 1.39
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res (1996) 1.35
Template images for nonhuman primate neuroimaging: 2. Macaque. Neuroimage (2001) 1.35
Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med (1995) 1.34
Copper-64-labeled antibodies for PET imaging. J Nucl Med (1992) 1.29
Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J Med Chem (1994) 1.29
Quantification of regional myocardial blood flow in vivo with H215O. Circulation (1984) 1.24
Vocal cord dysfunction in a child with asthma. J Asthma (1991) 1.23
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience (2006) 1.22
Subthalamic nucleus stimulation-induced regional blood flow responses correlate with improvement of motor signs in Parkinson disease. Brain (2008) 1.22
Pulmonary deposition of aerosols in children with cystic fibrosis. J Pediatr (1974) 1.22
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med (1995) 1.21
Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med (1991) 1.21
Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc Natl Acad Sci U S A (1996) 1.20
Putamen volume in idiopathic focal dystonia. Neurology (1998) 1.17
Scintigraphic detection of atherosclerotic lesions and venous thrombi in man by indium-111-labelled autologous platelets. Lancet (1978) 1.17
The measure in vivo of regional cerebral oxygen utilization by means of oxyhemoglobin labeled with radioactive oxygen-15. J Clin Invest (1970) 1.17
Positron emission tomographic measurement of cerebral blood flow and permeability-surface area product of water using [15O]water and [11C]butanol. J Cereb Blood Flow Metab (1987) 1.16
Quantitation of myocardial fatty acid metabolism using PET. J Nucl Med (1996) 1.15
High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol (1999) 1.15
Regional blood flow in hemiparkinsonism. Neurology (1985) 1.14
Photon time-of-flight-assisted positron emission tomography. J Comput Assist Tomogr (1981) 1.14
Abnormal cortical responses in patients with writer's cramp. Neurology (1993) 1.14
The measurement of regional ventilation in man: a new method of quantitation. J Nucl Med (1973) 1.13
Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes (2001) 1.13
Changes in brain activity during motor learning measured with PET: effects of hand of performance and practice. J Neurophysiol (1998) 1.12
Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. J Nucl Med (1977) 1.10
NCA 16 alpha-[18F]fluoroestradiol-17 beta: the effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity. Int J Rad Appl Instrum A (1986) 1.10
Effects of tea tree oil on Escherichia coli. Lett Appl Microbiol (1998) 1.09
Tomographic images of blood pool and perfusion in brain and heart. J Nucl Med (1976) 1.08
Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med (1984) 1.08
Inhaled steroids and severe viral infections. J Asthma (1994) 1.07
Comparison of four bifunctional chelates for radiolabeling monoclonal antibodies with copper radioisotopes: biodistribution and metabolism. Bioconjug Chem (1997) 1.06
Pill swallowing ability and training in children 6 to 11 years of age. Clin Pediatr (Phila) (2006) 1.06
Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med (2001) 1.06
Small animal imaging. current technology and perspectives for oncological imaging. Eur J Cancer (2002) 1.05
Radiotoxicity of 5-[123I]iodo-2'-deoxyuridine in V79 cells: a comparison with 5-[125I]iodo-2'-deoxyuridine. Radiat Res (1989) 1.05
Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons. J Nucl Med (1996) 1.05
In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med (1995) 1.04
Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography. Circ Res (1992) 1.04
Determination of octanol-water partition coefficient for terpenoids using reversed-phase high-performance liquid chromatography. J Chromatogr A (1999) 1.03
Acute Pneumonitis-an Atypical Bronchopneumonia of virus Origin. Can Med Assoc J (1942) 1.03
Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.03
Neural correlates of STN DBS-induced cognitive variability in Parkinson disease. Neuropsychologia (2008) 1.03
PET imaging of hypoxia. Q J Nucl Med (2001) 1.03
Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med (2000) 1.01
Pathophysiology of parkinsonism due to hydrocephalus. J Neurol Neurosurg Psychiatry (2004) 1.01
Tracer-kinetic models for measuring cerebral blood flow using externally detected radiotracers. J Cereb Blood Flow Metab (1987) 1.01
Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study. Mov Disord (2005) 1.01